ENXTPA:SANPharmaceuticals
Will New Dupixent Data and AI Investment Shift Sanofi's (ENXTPA:SAN) Innovation-Led Growth Narrative?
Earlier this month, Sanofi and Regeneron reported REMODEL Phase 4 data showing Dupixent improved esophageal structure and function in adults with eosinophilic esophagitis, while Sanofi also expanded its Toronto AI Centre of Excellence with a US$294 million investment supported by a conditional grant of up to US$5 million.
These advances in both a leading biologic and AI-enabled R&D and manufacturing deepen Sanofi’s foothold in immunology and vaccines, underlining its push to scale innovation...